A20 Protein Liver Overexpression for Glycemic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperglycemia, diabetes, pre-diabetes, and metabolic syndrome are often ineffective and costly, with a pressing need for therapies that can mitigate, halt, or reverse glucose dysregulation-related conditions without causing hypoglycemia.
Innovation Solution
Overexpression of A20 in the liver, achieved through methods such as recombinant adenoviral gene transfer or AAV vector-mediated gene therapy, which upregulates A20 expression to restore glycemic control in an insulin-independent manner, improving local hepatic glucose metabolism and systematically impacting glucose regulation in other organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for diabetes and hyperglycemia, then glycemic control is attempted, but hypoglycemia is caused and treatment effectiveness is reduced
Solution Approach 1:
The invention changes the therapeutic approach from insulin-based glycemic control to A20 protein-mediated metabolic regulation. By administering A20 protein or nucleic acids encoding A20, the patent achieves glycemic control through a different biochemical pathway that does not cause hypoglycemia, thus resolving the contradiction between effective glycemic control and avoidance of harmful hypoglycemic effects
Solution Approach 2:
The invention introduces A20 protein as an intermediary substance that mediates glycemic control. Rather than directly administering insulin that causes hypoglycemia, the patent uses A20 as a mediator that regulates glucose metabolism through alternative mechanisms, including modulation of inflammatory responses and metabolic pathways, thereby achieving glycemic control without the harmful side effect of hypoglycemia
2Reliability
If current diabetes therapies are administered, then blood glucose is targeted, but treatment cost increases and convenience decreases
Solution Approach 1:
The invention enables the body's own cells to produce the therapeutic agent. By administering nucleic acids encoding A20 (such as plasmids or viral vectors), the patent allows hepatocytes to autonomously produce A20 protein, eliminating the need for continuous external administration of insulin or other diabetes medications. This self-service approach improves treatment convenience while maintaining reliable glucose regulation
Solution Approach 2:
The invention uses nucleic acid copies (plasmids or viral vectors containing A20 gene sequences) to deliver the therapeutic information to liver cells. These nucleic acid copies serve as templates that instruct cells to produce A20 protein, providing a sustainable source of the therapeutic agent without requiring repeated administration of expensive diabetes medications, thus improving both convenience and cost-effectiveness
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2~3B
AI summary
The disclosure relates to the use of A20 to restore glycemic control in a subject in need thereof, for example, a subject having diabetes. This novel approach provides non-insulin based therapy for diabetes.